Use of Nintedanib for the Treatment of Systemic Sclerosis-associated Interstitial Lung Disease at Expert Scleroderma Centers in the United States

By sjmartinez • April 11, 2025

Luo Y, Assassi S, Mayes MD, Frech TM, Steen VD, Richardson C, Chung L, Sandorfi N, VanBuren JM, Harding M, Alvey JS, Skaug B, McMahan Z, Lakin KS, Zahn C, Bracken SJ, Lebiedz-Odrobina DJ, Molitor JA, Evnin LB, Moore DF, Shah A, Castelino FV, Volkmann ER, Hant FN, Makol A, Shah AA, Hummers LK, Gordon JK, Khanna D, Bernstein EJ. Use of Nintedanib for the Treatment of Systemic Sclerosis-associated Interstitial Lung Disease at Expert Scleroderma Centers in the United States. Ann Am Thorac Soc. 2025 Apr 10. doi: 10.1513/AnnalsATS.202410-1045RL. Epub ahead of print. PMID: 40208257.

Tags: Publications, Rheumatology

Related Posts

Moderators of the Effects of Telehealth Mindfulness-based Interventions for Chronic Pain: A Secondary Responder Analysis of the LAMP Randomized Controlled Trial

Calvert CM, Hagel Campbell EM, Cross LJS, Bangerter A, Bronfort G, Evans R, Meis LA, Haley A, Leininger B, Matthias M, Polusny M, Allen K,[...]

Leveraging scholarship to lead

Moriates C. Leveraging scholarship to lead. J Hosp Med. 2026 Sep 9. doi: 10.1002/jhm.70478. Epub ahead of print. PMID: 42717657.

Fatty Acid and Oxylipin Metabolism Differentiate Isolated Postcapillary From Combined Pre- and Postcapillary Pulmonary Hypertension

Alotaibi M, Tang A, Sun N, Gurholt I, Yuguchi E, Roberts K, Preston I, Warburton R, Yuan JX, Kim NH, Chan SY, Jain M, Cheng[...]